BioCaptiva has developed BIOCAPTOR, a medical device that captures cfDNA.
Prototype testing shows that the device has the potential to greatly enhance detection of early-stage cancers in patients without the need for surgical biopsy. It could also pave the way for new approaches to disease monitoring, resulting in better outcomes for patients.
BIOCAPTOR works alongside a standard apheresis machine, filtering cfDNA (circulating free DNA) from the patient’s blood system. It captures cfDNA in much greater quantities than the current standard of a single blood draw. It can therefore overcome a significant current limitation of cancer liquid biopsy testing.